AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12829989 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon or interferon alfa-2b and ribavirin
Number of subjects: 1428
Study 12829989 — intervention group
Group type: COMPARATOR
Intervention: Control group (other genotypes)
Number of subjects: 1428
Study 10985648 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 0
Study 10985648 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin
Number of subjects: 0
Study 10985648 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid/Rifampicin regimen
Number of subjects: 0
Study 10985648 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (without rifampicin)
Number of subjects: 0
Study 10985648 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin (or rifapentine) alone
Number of subjects: 0
Study 10985648 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of rifampicin
Number of subjects: 0
Study 8675921 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercises (walking, stepping up and down from benches), aerobic dancing, and flexibility exercises for 60 minutes, three times a week, over a period of 12 months
Number of subjects: 124
Study 8675921 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 124
Study 1511814 — intervention group
Group type: COMPARATOR
Intervention: Immediate injection sclerotherapy (group A)
Number of subjects: 60
Study 1511814 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy preceded by balloon tamponade (group B)
Number of subjects: 60
Study 6396365 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase 1.5 X 10(6) units/90 minutes
Number of subjects: 33
Study 6396365 — intervention group
Group type: COMPARATOR
Intervention: Routine continuous i.v. heparin treatment (1000 units/h)
Number of subjects: 33
Study 31427346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal counselling (IPC)
Number of subjects: 60
Study 31427346 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 60
Study 30020205 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation (CR) training
Number of subjects: 20
Study 26825278 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to quadriceps muscles bilaterally from the first postoperative day until ICU discharge for a maximum of 14 days.
Number of subjects: 54
Study 26825278 — intervention group
Group type: COMPARATOR
Intervention: Control group with electrodes applied but no electricity delivered.
Number of subjects: 54
Study 26825278 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 54
Study 24657991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Condition (IC): Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Number of subjects: 1059
Study 24657991 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC): Printed patient education material and hypertension treatment guidelines for physicians.
Number of subjects: 1059
Study 24657991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Condition (IC) in patients without diabetes mellitus: Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Number of subjects: 1059
Study 24657991 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) in patients without diabetes mellitus: Printed patient education material and hypertension treatment guidelines for physicians.
Number of subjects: 1059
Study 24657991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Condition (IC) in small-sized community health centers: Patient education, home BP monitoring, monthly lifestyle counseling, and physicians attending monthly hypertension case rounds with feedback on home BP readings.
Number of subjects: 1059
Study 24657991 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) in small-sized community health centers: Printed patient education material and hypertension treatment guidelines for physicians.
Number of subjects: 1059
Study 22018821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoalveolar moulding (NAM) within 1 month of age
Number of subjects: 15
Study 22018821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasoalveolar moulding (NAM) between 1 and 5 months of age
Number of subjects: 15
Study 22018821 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐cleft 18‐month old children)
Number of subjects: 15
Study 20015855 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice Stepping Reaction Time (CSRT) test
Number of subjects: 294
Study 20015855 — intervention group
Group type: EXPERIMENTAL
Intervention: CSRT performance
Number of subjects: 294
Study 20015855 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological parameters (reaction time and balance performance)
Number of subjects: 294
Study 20015855 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strength and visual contrast sensitivity
Number of subjects: 294
Study 20015855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing
Number of subjects: 294
Study 17686184 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised aerobic exercise program (ImPACT Program)
Number of subjects: 40
Study 17686184 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 40
Study 15543117 — intervention group
Group type: EXPERIMENTAL
Intervention: A combination of inhaled medical air and titrated intravenous midazolam
Number of subjects: 65
Study 15543117 — intervention group
Group type: EXPERIMENTAL
Intervention: A combination of inhaled 40% nitrous oxide in oxygen and titrated intravenous midazolam
Number of subjects: 65
Study 15543117 — intervention group
Group type: EXPERIMENTAL
Intervention: A combination of an inhaled mixture of 0.3% sevoflurane and 40% nitrous oxide in oxygen with titrated intravenous midazolam
Number of subjects: 65
Study 15543117 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 65
Study 11463590 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of deep inspiration during methacholine inhalation
Number of subjects: 8
Study 11463590 — intervention group
Group type: COMPARATOR
Intervention: Allowed deep inspiration during methacholine inhalation
Number of subjects: 8
Study 9529467 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose
Number of subjects: 119
Study 9529467 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 119
Study 9529467 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 119
Study 7994787 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg FARM by intravesical instillation every 2-4 weeks for 1 year
Number of subjects: 73
Study 7994787 — intervention group
Group type: COMPARATOR
Intervention: 30 mg ADR by intravesical instillation every 2-4 weeks for 1 year
Number of subjects: 73
Study 7994787 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg FARM
Number of subjects: 73
Study 7994787 — intervention group
Group type: COMPARATOR
Intervention: 30 mg ADR
Number of subjects: 73
Study 2521868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine treatment
Number of subjects: 0
Study 2521868 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 0
Study 173124 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural ACTH
Number of subjects: 20
Study 173124 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic ACTH
Number of subjects: 20
Study 173124 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural and Synthetic ACTH
Number of subjects: 20
Study 31797399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12® (1 × 10^9 CFU/day)
Number of subjects: 80
Study 31797399 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB-12®
Number of subjects: 80
Study 31797399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31455897 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimizing energy and protein intake
Number of subjects: 117
Study 31455897 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (1 kilo increase)
Number of subjects: 117
Study 29284715 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: risk assessment using a validated tool (AUSDRISK)
Number of subjects: 10304
Study 29284715 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: AUSDRISK assessment followed by point‐of‐care glycated haemoglobin testing
Number of subjects: 10304
Study 29284715 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: AUSDRISK assessment followed by point‐of‐care blood glucose testing
Number of subjects: 10304
Study 29284715 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 10304
Study 29284715 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic outcome measure
Number of subjects: 10304
Study 25679122 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus naltrexone and clinical case management
Number of subjects: 138
Study 25679122 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus naltrexone and clinical case management
Number of subjects: 138
Study 25916132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous laser therapy (ILIB‐405) along with traditional drug treatment (proton pump inhibitors, antacids, prokinetics) in the main group (70 patients).
Number of subjects: 102
Study 25916132 — intervention group
Group type: COMPARATOR
Intervention: Traditional drug treatment (control group, 30 patients).
Number of subjects: 102
Study 25916132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous laser therapy (ILIB‐405) along with traditional drug treatment in the main group (70 patients).
Number of subjects: 102
Study 21975041 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilation
Number of subjects: 2556
Study 21975041 — intervention group
Group type: EXPERIMENTAL
Intervention: Epilation in patients with severe entropion
Number of subjects: 2556
Study 19207889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic debridement (UD)
Number of subjects: 33
Study 19207889 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) with hand instruments
Number of subjects: 33
Study 17401693 — intervention group
Group type: COMPARATOR
Intervention: Phosphate supplement
Number of subjects: 16
Study 17401693 — intervention group
Group type: COMPARATOR
Intervention: Meat
Number of subjects: 16
Study 17401693 — intervention group
Group type: COMPARATOR
Intervention: Cheese
Number of subjects: 16
Study 15321804 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg), vitamin B‐12 (0.4 mg)
Number of subjects: 90
Study 15321804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B‐6 (40 mg)
Number of subjects: 90
Study 15321804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 15321804 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) and vitamin B‐12 (0.4 mg) with additional folic acid (5 mg/d) for the first 2 weeks
Number of subjects: 90
Study 11254913 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hormone replacement therapy (17beta-estradiol plus medroxyprogesterone acetate)
Number of subjects: 3
Study 11254913 — intervention group
Group type: COMPARATOR
Intervention: Estrogen replacement therapy (ERT) alone (either 17beta-estradiol (1 mg) or conjugated equine estrogens (CEE) (0.625 mg))
Number of subjects: 3
Study 11254913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 9677811 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant product based on extracts of Salvia officinalis (sage) and Medicago sativa (alfalfa)
Number of subjects: 30
Study 7793393 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 2606
Study 7793393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2606
Study 7793393 — intervention group
Group type: COMPARATOR
Intervention: Patients with wall motion index > 1.2
Number of subjects: 2606
Study 2196149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily
Number of subjects: 55
Study 2196149 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg over 8 hr for 5 days or longer
Number of subjects: 55
Study 2196149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 55
Study 2196149 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 55
Study 160237 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.16 mg kg‐1
Number of subjects: 0
Study 30764646 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Stepping Stones Triple P (GSSTP)
Number of subjects: 84
Study 30764646 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 84
Study 28109939 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led teaching
Number of subjects: 86
Study 28109939 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-assisted learning
Number of subjects: 86
Study 25492571 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil target concentration 0 ng/ml
Number of subjects: 75
Study 25492571 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil target concentration 1 ng/ml
Number of subjects: 75
Study 25492571 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil target concentration 2 ng/ml
Number of subjects: 75
Study 24476018 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Swab-Scrub
Number of subjects: 192
Study 24476018 — intervention group
Group type: COMPARATOR
Intervention: Group Control
Number of subjects: 192
Study 22896735 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimin 90 (MM)
Number of subjects: 20
Study 22896735 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 19602786 — intervention group
Group type: EXPERIMENTAL
Intervention: EE/CA plus metformin (1,700 mg, cyproterone acetate 2 mg, ethinylestradiol 35 microg)
Number of subjects: 40
Study 19602786 — intervention group
Group type: COMPARATOR
Intervention: EE/CA (cyproterone acetate 2 mg, ethinylestradiol 35 microg)
Number of subjects: 40
Study 17868239 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion nurse intervention
Number of subjects: 281
Study 14678372 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 265
Study 14678372 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 265
Study 14678372 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 20 mg
Number of subjects: 265
Study 14678372 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 2 mg
Number of subjects: 265
Study 14678372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 14678372 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg and 10 mg
Number of subjects: 265
Study 14678372 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine
Number of subjects: 265
Study 11743286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of leuprolide plus flutamide before radical prostatectomy
Number of subjects: 282
Study 11743286 — intervention group
Group type: COMPARATOR
Intervention: Prostatectomy only
Number of subjects: 282
Study 9825973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.25 mg kg(‐1) b.i.d. on d 1‐7; 0.12 mg kg(‐1) b.i.d. on d 8‐14; 0.05 mg kg(‐1) b.i.d. on d 15‐21; 0.02 mg kg(‐1) b.i.d. on d 22‐28)
Number of subjects: 49
Study 9825973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 49
Study 9825973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7663802 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-lipoxygenase inhibitor (zileuton)
Number of subjects: 12
Study 7663802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2667313 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating-calorie diet with exercise
Number of subjects: 0
Study 2667313 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant-calorie diet with exercise
Number of subjects: 0
Study 2667313 — intervention group
Group type: COMPARATOR
Intervention: Alternating-calorie diet without exercise
Number of subjects: 0
Study 2667313 — intervention group
Group type: COMPARATOR
Intervention: Constant-calorie diet without exercise
Number of subjects: 0
Study 656270 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 750 mg daily
Number of subjects: 10
Study 656270 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 10
Study 656270 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 10
Study 656270 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate 2 g daily
Number of subjects: 10
Study 30592235 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser plus NB-UVB
Number of subjects: 30
Study 30592235 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB alone
Number of subjects: 30
Study 27838276 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar anodal tDCS (5 days/week for 2 weeks)
Number of subjects: 20
Study 27838276 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 26033312 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2 mg·kg(‐1) (0.8 ml·kg(‐1))
Number of subjects: 91
Study 26033312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 1 μg·kg(‐1)
Number of subjects: 91
Study 26033312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 2 μg·kg(‐1)
Number of subjects: 91
Study 26033312 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2 mg·kg(‐1)
Number of subjects: 91
Study 26033312 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg·kg(‐1) + dexmedetomidine 1 μg·kg(‐1) and 2 μg·kg(‐1)
Number of subjects: 91
Study 23868620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid (UDCA) 300-450 mg/d
Number of subjects: 87
Study 23868620 — intervention group
Group type: COMPARATOR
Intervention: Diet (1200 Kcal/d for females, 1500 Kcal/d for males)
Number of subjects: 87
Study 21810646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette withdrawal (heavy smoking)
Number of subjects: 48
Study 20469779 — intervention group
Group type: EXPERIMENTAL
Intervention: R + G; basal‐bolus regular and glargine insulin (R‐R‐R‐G)
Number of subjects: 172
Study 20469779 — intervention group
Group type: COMPARATOR
Intervention: Premix 30/70 and R + NPH regimens
Number of subjects: 172
Study 16955801 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly reconstituted rhTSH (91.5 microg IV)
Number of subjects: 12
Study 16955801 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted and stored rhTSH at 4 degrees C for 4 weeks
Number of subjects: 12
Study 16955801 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted and frozen rhTSH at -20 degrees C for 8 weeks
Number of subjects: 12
Study 17141640 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Research Arm Test (ARAT)
Number of subjects: 50
Study 17141640 — intervention group
Group type: EXPERIMENTAL
Intervention: ARAT scores
Number of subjects: 50
Study 12595976 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-chamber drainage system (TCDS)
Number of subjects: 311
Study 12595976 — intervention group
Group type: COMPARATOR
Intervention: Complex closed drainage system (CCDS)
Number of subjects: 311
Study 12595976 — intervention group
Group type: EXPERIMENTAL
Intervention: TCDS
Number of subjects: 311
Study 12595976 — intervention group
Group type: COMPARATOR
Intervention: CCDS
Number of subjects: 311
Study 10368943 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sentences
Number of subjects: 0
Study 10368943 — intervention group
Group type: COMPARATOR
Intervention: Randomized words (nouns)
Number of subjects: 0
Study 10368943 — intervention group
Group type: COMPARATOR
Intervention: Randomized words (prepositions)
Number of subjects: 0
Study 8901660 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/d aspirin
Number of subjects: 409
Study 8901660 — intervention group
Group type: COMPARATOR
Intervention: 650 mg/d aspirin
Number of subjects: 409
Study 2057272 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician counseling and take-home pamphlets
Number of subjects: 334
Study 2057272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 334
Study 2057272 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone counseling (additional counseling)
Number of subjects: 334
Study 6190548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high-dose cis-platinum, Oncovin (vincristine) and bleomycin (COB)
Number of subjects: 0
Study 6190548 — intervention group
Group type: COMPARATOR
Intervention: Weekly methotrexate (MTX)
Number of subjects: 0
Study 29996127 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened T50 (minutes)
Number of subjects: 685
Study 29996127 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced fetuin‐A concentrations (g/L)
Number of subjects: 685
Study 29996127 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated high sensitivity c-reactive protein (hsCRP)
Number of subjects: 685
Study 28807912 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A (3,600 mg)
Number of subjects: 100
Study 28807912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28807912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir (standard oral dose)
Number of subjects: 100
Study 26611872 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent exercise training
Number of subjects: 32
Study 26611872 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 32
Study 26611872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 32
Study 23730881 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 21264786 — intervention group
Group type: EXPERIMENTAL
Intervention: Brassicaceae vegetables (small-scale 9-day human experiment)
Number of subjects: 0